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Alzheimer’s disease (AD) is characterized by memory impairment, neurochemically by accumulation of -amyloid peptide (namely
A1-42) and morphologically by an initial loss of nerve terminals. Caffeine consumption prevents memory dysfunction in different
models, which is mimicked by antagonists of adenosine A2A receptors (A2ARs), which are located in synapses. Thus, we now tested
whether A2AR blockade prevents the early A1-42-induced synaptotoxicity andmemory dysfunction and what are the underlying signal-
ing pathways. The intracerebral administration of soluble A1-42 (2 nmol) in rats or mice caused, 2 weeks later, memory impairment
(decreased performance in the Y-maze and object recognition tests) and a loss of nerve terminal markers (synaptophysin, SNAP-25)
without overt neuronal loss, astrogliosis, or microgliosis. These were prevented by pharmacological blockade [5-amino-7-(2-
phenylethyl)-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (SCH58261); 0.05 mg  kg1  d1, i.p.; for 15 d] in rats, and
genetic inactivation of A2ARs inmice.Moreover, thesewere synaptic events since purified nerve terminals acutely exposed toA1-42 (500
nM) displayedmitochondrial dysfunction, which was prevented by A2AR blockade. SCH58261 (50 nM) also prevented the initial synapto-
toxicity (loss of MAP-2, synaptophysin, and SNAP-25 immunoreactivity) and subsequent loss of viability of cultured hippocampal
neurons exposed to A1-42 (500 nM). This A2AR-mediated control of neurotoxicity involved the control of A1-42-induced p38 phosphor-
ylation and was independent from cAMP/PKA (protein kinase A) pathway. Together, these results show that A2ARs play a crucial role in
the development of A-induced synaptotoxicity leading to memory dysfunction through a p38 MAPK (mitogen-activated protein
kinase)-dependent pathway and provide a molecular basis for the benefits of caffeine consumption in AD.
Introduction
Alzheimer’s disease (AD) is the most common chronic neurode-
generative disease and is clinically characterized by a progressive
impairment of cognitive functions such as learning andmemory.
Although the traditional neuropathologic hallmarks of AD are
the presence of neurofibrillary tangles and the accumulation of
the senile plaques resulting from -amyloid peptide (A) aggre-
gation, the neurochemical parameter best correlated with mem-
ory dysfunction in AD is the levels of soluble A, mainly A1-42
(Selkoe, 2001). Also, the earliest morphological trait and the best
correlated with initial memory impairment in AD is the loss of
synapses in the limbic cortex, namely in the hippocampus
(Coleman et al., 2004). In fact, synapses seem to be the primordial
target of toxic A oligomers, with the resulting synaptic failure
underlyingmemory impairment in AD (Hardy and Selkoe, 2002;
Klein et al., 2004). Thus, the earlyA1-42-induced synaptotoxicity
and associatedmechanisms constitute major targets in the devel-
opment of novel therapeutic strategies for AD.
Adenosine modulates synaptic transmission through inhibi-
tory A1 or facilitatory A2A receptors (A2ARs), both of which are
predominantly located in synapses, namely in the limbic and
neocortex (Fredholm et al., 2005). Given the ability of A1Rs to
inhibit calcium entry into neurons, glutamate release, and
NMDA receptor activation, A1Rs have been considered promis-
ing candidate targets to prevent neuronal damage. However,
their rapid downregulation and functional desensitization after
insults limits their neuroprotective potential (deMendonc¸a et al.,
2000). More recently, major interest has been devoted to A2ARs
since their blockade affords neuroprotection against chronic in-
sults in the adult brain (Cunha, 2005; Chen et al., 2007), which
also triggermajor increases in the extracellular levels of adenosine
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(deMendonc¸a et al., 2000). This is in notable agreement with the
ability of caffeine (a nonselective adenosine receptor antagonist)
to protect against cognitive impairment in different animalmod-
els, an effect that mainly seems to involve A2ARs (for review, see
Cunha, 2008b; Takahashi et al., 2008). Likewise, caffeine con-
sumption inversely correlates with the incidence of AD (Maia
and de Mendonc¸a, 2002) and prevents memory impairment in
animal models of AD (Arendash et al., 2006; Dall’Igna et al.,
2007), an effect mimicked by selective A2AR antagonists
(Dall’Igna et al., 2007). Interestingly, A2AR blockade selectively
preventedA-induced, but not scopolamine- or dizocilpinemal-
eate (MK801)-induced, memory impairment (Cunha et al.,
2008). Notably, memory impairment by A (but not scopol-
amine or MK801) involves synaptotoxicity. This suggests that
A2AR blockade prevents memory impairment by selectively con-
trolling synaptotoxicity, which would provide a molecular basis
to support a neuroprotective action of A2ARs.
The present study tested the ability of A2ARs to prevent A1-42-
induced synaptotoxicity and memory impairment and investi-
gated the underlying mechanisms. Results show that A2AR
blockade (pharmacologic or genetic) prevents A1-42-induced
synaptotoxicity and subsequent memory dysfunction by amech-
anism involving the control of the p38mitogen-activated protein
kinase (MAPK) pathway.
Materials andMethods
Animals. Wistar rats (8–10 week males) were from Charles River.
C57BL/6 mice (8–10 week males), both wild-type (WT) and A2AR
knock-out (KO), were generously provided by Jiang-Fan Chen (Univer-
sity of Boston, Boston, MA). Animals were maintained under controlled
environment (23 2°C; 12 h light/dark cycle; ad libitum access to food
and water) and handled according to European Union guidelines (86/
609/EEC). Behavioral experiments were conducted between 10:00 A.M.
and 4:00 P.M.
Analysis of -amyloid peptides and in vivo administration procedures.
The -amyloid (1-42) peptide fragment (A1-42) or the nonamyloido-
genic reverse peptide A42-1 (A42-1) was dissolved in water at a concen-
tration of 2.25 mg/ml and 2 nmol in 4 l was administered
intracerebroventricularly, as previously described (Dall’Igna et al.,
2007). Control animals were intracerebroventricularly infused with a
similar volume of water. Behavioral analysis was performed 2 or 15 d
after A1-42 or A42-1 administration. The selective A2AR antagonist
5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo
[1,5-c]pyrimidine (SCH58261) (generouslyprovidedbyScottWeiss,Verna-
lis, Wokingham, UK) was injected intraperitoneally at an efficacious dose
(0.05mg/kg of SCH58261) (Cunha et al., 2006, 2008; Dall’Igna et al., 2007),
in saline (0.9% sodium chloride) with 10%dimethylsulfoxide, applied daily
starting 30minbeforeA1-42 administration.Control animalswere injected
intraperitoneally with saline with 10% dimethylsulfoxide.
The qualitative analysis of the oligomerization status of the A peptide
solution was evaluated byWestern blot analysis using the 6E10 antibody
that recognizes different human A homomeric forms, as previously
described (Evans et al., 2008). Briefly, 10l of the different batches of A
solutions was mixed with sample buffer (40% glycerol, 2% SDS, 0.2 M
Tris-HCl, pH 6.8, and 0.005% Coomassie blue) and analyzed by electro-
phoresis (40 mA for 3 h and 30 min) using a tricine running buffer
(Gibson et al., 2004). The blots were revealedwithCoomassie blue (using
a Coomassie blue R-250 solution made of 40% methanol, 10% acetic
acid, and 0.1%Coomassie blue R-250 for 30min, followed by destaining
with 40%methanol and 10% acetic acid) or with 6E10 antibody (1:1000
dilution; Covance), as described below (see Western blot analysis).
The A1-42 levels in the hippocampus were quantified using two
ELISA kits (Invitrogen), one detecting A1-42 (and isoforms with lower
length) and the other A1-40, as previously described (Cao et al., 2009).
Briefly, one hippocampus was homogenized in RIPA buffer (100 mM
Tris, pH 8.0, 150 mM NaCl, 0.5% deoxycholate, 1% IGEPAL, 0.2% SDS,
and protease inhibitor mixture containing leupeptin, pepstatin A, chy-
mostatin, and aprotinin, all 1 mg/ml from Sigma-Aldrich). The mixture
was centrifuged (30min at 27,000 g) and the supernatant was stored at
80°C until ELISA quantifications, which were performed following the
manufacturer’s instructions. A1-42 levels were estimated by subtracting
the estimated amount of A1-40 from those of A1-42 and were normal-
ized by tissue weight and/or amount of protein, determined with the
bicinchoninic acid (BCA) method (Pierce Biotechnology).
The detection of A aggregates in the hippocampus was performed
using Congo Red (Puchtler et al., 1985) or Thioflavin-S histochemical
analysis (Reyes et al., 2004) of hippocampal sections (see below), as pre-
viously described (Melo et al., 2009).
Behavioral analysis. Locomotor activity was monitored in an open-
field arena (50  50 cm, divided in four squares of 25 cm for rats, and
30  30 cm, divided in nine squares for mice, respectively), and the
exploratory behavior of the animals was evaluated by counting the total
number of line crossings and the number of rearings over a 5min period.
Hippocampal-dependentmemory performancewas assessed bymeasur-
ing spontaneous alternation performance during 8 min in the Y-maze
test, which allows evaluating cognitive searching behavior, although it
does not allow isolating memory performance (for review, see Hughes,
2004). The series of arm entries was recorded visually and an alternation
was defined as entries in all three arms on consecutive occasions. The
percentage of alternation was calculated as follows: total of alternations/
(total arm entries  2), as previously described (Dall’Igna et al., 2007).
Memory performance was also evaluated using the object recognition
test consisting of two 3 min sessions (24 h after habituation): the first
with two identical objects (training session) and the second (test session,
30 min after) with two dissimilar objects (a familiar and a novel one);
recognition object index was calculated by the ratio of the time spent
exploring novel object over the total exploration time of both objects, as
previously described (Costa et al., 2008b). The experimenter conducting
behavioral analysis was blinded to treatment conditions.
Histochemistry and immunohistochemistry. Brain fixation was per-
formed through transcardiac perfusion with 4% paraformaldehyde
(in 0.9% sodium chloride and 4% sucrose), as previously described
(Cunha et al., 2006). Frozen brain were sectioned (20 m coronal
slices) with a Leica CM1850 cryostat (Leica Microsystems), mounted
on slides coated with 2% gelatin with 0.08% chromalin (chromium
and potassium sulfate), allowed to dry at room temperature, and
stored at 20°C until use.
Neuronal morphology in hippocampal sections was evaluated by cr-
esyl violet staining of Nissl bodies, as previously described (Lopes et al.,
2003). Briefly, sections were incubated for 10 min with cresyl violet
(Sigma-Aldrich) solution (0.5% in acetate buffer). Sections were then
washed twice with acetate buffer, twice in 100% ethanol, cleared with
xylene, and mounted with Vector medium (Vector Laboratories). De-
generating neurons were detected using Fluoro-Jade C, which fluores-
cently labels them independently of the mechanism of cell death
(Schmued et al., 2005). We used a 0.0001% solution of Fluoro-Jade C
(Histo-Chem), as previously described (Cunha et al., 2006).
Detection of nerve terminals was performed as previously described
(Cunha et al., 2006), using immunohistochemical detection of synapto-
physin, a protein located in synaptic vesicles (Masliah and Terry, 1993).
Immunohistochemistry detection of CD11b (a marker of microglia)
(Jensen et al., 1997) andof glial fibrillary acidic protein (GFAP) (amarker
of astrocytes) (Pekny and Nilsson, 2005) was performed to evaluated
microgliosis and astrogliosis, respectively. The sections were first rinsed
for 5 min with PBS (140 mM NaCl, 3 mM KCl, 20 mM Na2HPO4, 1.5 mM
KH2PO4) and then three times for 5 min with Trizma base solution
(TBS) (0.05 M containing 150 mM NaCl, pH 7.2) at room temperature.
Sections were then permeabilized and blockedwith TBS containing 0.2%
Triton X-100 and 10% goat serum during 45 min, incubated in the
presence of the mouse anti-synaptophysin antibody (1:500) or rat anti-
CD11b (1:600; Serotec) or anti-GFAP-Cy3 (1:500; Sigma-Aldrich) for
72 h at 4°C, rinsed three times for 10 min in TBS, and subsequently
incubatedwith goat anti-mouse or goat anti-rat secondary antibody con-
jugated with a fluorophore (Alexa Fluor 488; Invitrogen) (1:100) for 2 h
at room temperature. After rinsing twice for 10 min in TBS and once for
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10 min in distilled water, the sections were dehydrated and passed
through xylene before mounting on slides, using Vectashield mounting
medium (Vector Laboratories).
All sections were examined under a transmission and fluorescence
Zeiss Axiovert 200 microscope, with AxioVision software 4.6
(PG-HITEC).
Assays in hippocampal synaptosomes. Synaptosomes (i.e., enriched
nerve terminals) were prepared from the hippocampus using a sucrose/
Percoll-based series of centrifugations, as previously described (Rebola et
al., 2005). Briefly, the two hippocampi from one animal were homoge-
nized at 4°C in sucrose solution (0.32 M) containing 1 mM EDTA, 10 mM
HEPES, 1 mg/ml bovine serum albumin (BSA), and 1 mM dithiothreitol
(DTT), pH 7.6, centrifuged at 3000 g for 10 min at 4°C, the superna-
tants were collected and centrifuged at 14,000 g for 12 min at 4°C, and
the pellet was resuspended in 1 ml of a 45% (v/v) Percoll solution in
Krebs’ buffer (140 mM NaCl, 5 mM KCl, 25 mM HEPES, 1 mM EDTA, 10
mM glucose, pH 7.4). After centrifugation at 14,000 g for 2 min at 4°C,
the top layer was removed (synaptosomal fraction) andwashed in 1ml of
Krebs’ buffer. Protein determination was performed with the BCA
method.
The redox status of synaptosomes, known to be affected by exposure to
-amyloid peptides (Mattson et al., 1998), wasmeasured by a colorimet-
ric assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) (Sigma-Aldrich), as previously described (Silva et al.,
2007). Synaptosomes were incubated for 2 h at 37°C in Krebs’ buffer in
the absence or presence of A1-42 (500 nM) and/or SCH58261 (50 nM).
MTT (0.5 mg/ml) was then added and incubated for 1 h at 37°C in the
dark. AsMTT is converted to a water-insoluble blue product (formazan)
by viable terminals, the precipitated dye can be spectrophotometrically
(570 nm) quantified after exposing synaptosomes to isopropanol con-
taining 0.04 M HCl. Values were expressed as the percentage of optical
density of control synaptosomes, in the absence of added drugs.
The mitochondrial membrane potential of synaptosomes was mea-
sured by a fluorimetric assay adapted and optimized for synaptosomes
from a fluorimetric protocol used in isolated brain mitochondria
(Oliveira et al., 2007). Synaptosomes were incubated for 2 h at 37°C in
Krebs’ buffer in the absence or presence of A1-42 (500 nM) and/or
SCH58261 (50 nM), followed by 1 h incubation with 2 nM tetramethyl
rhodamine methyl ester (TMRM) (Invitrogen) and a short-spin cen-
trifugation. The pellet was resuspended in 150l of Krebs–HEPESwith 2
nMTMRM. The functional assay was performed in a fluorescence spec-
trometer (Spectra Max Gemini EM; Molecular Devices), using 540 nm
excitation and 590 nm emission, with a cutoff of 570 nm, and analyzed
with SoftMax ProV5 (MolecularDevices). The experiment is initiated by
measuring a baseline (370 8 fluorescent arbitrary units; n 8) for 10
min, followed by the simultaneous addition of carbonyl cyanide
p-(trifluoromethoxy)phenylhydrazone (FCCP) (2 M) and oligomycin
(1 g/ml) and sequential measurement during 10 min to establish the
new baseline yielding a change of relative fluorescence of 607 28 fluo-
rescent arbitrary units (control, n  8). The effect of tested drugs was
measured as changes in this difference between final and initial baseline
and are expressed as the percentage of the difference observed in control
conditions.
Primary cultures of neurons.Hippocampal neuronswere cultured from
17- to 19-d-old Wistar rat embryos, as previously described (Silva et al.,
2007), and plated on poly-D-lysine-coated 16-mm-diameter coverslips
or six-well plates at densities of 5  104/coverslip (viability and immu-
nocytochemistry assays) or 1  106/well (Western blot analysis). Neu-
rons were grown at 37°C in a 5% CO2 humidified atmosphere in
Neurobasal medium with B-27 supplement, glutamate (25 M), glu-
tamine (0.5 mM), and gentamicin (0.12 mg/ml).
Drug treatments and evaluation of cell death. A1-42-induced neuronal
damagewas evaluated after culturing the neurons for 5–7 d. After 1week,
the culture matures and forms functional synaptic connections, and
most of the regions exhibit spontaneous synaptic transmission (Rui et al.,
2006). Either A1-42 (500 nM) or A42-1 (500 nM) were directly added to
the medium and incubated for 12–48 h. To test the ability of any drug
[SCH58261, 8-Br-cAMP, or N-[2-((o-bromocinamyl)amino)ethyl]-5-
isoquinolinesulfonamide (H-89) from Sigma-Aldrich or 4-(4-fluoro-
phenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole (SB202190) from
Tocris] to modify the effects of A1-42, these drugs were added 15 min
before addition of A1-42 onward.
Viability assays were performed by double labeling (3min incubation)
with the fluorescent probes Syto-13 (4M) and propidium iodide (PI) (4
g/ml; Invitrogen) followed by fluorescence microscopy cell counting.
As previously described (Silva et al., 2007), viable neurons present nuclei
homogenously labeled with Syto-13 (green fluorescent nuclei), whereas
apoptotic neurons show condensed and fragmented nuclei labeled with
Syto-13 (primary apoptosis) or with Syto-13 plus PI (secondary apopto-
sis) and necrotic neurons present intact nuclei labeled with PI (red fluo-
rescent nuclei). Each experiment was repeated using different cell
cultures in duplicate, and cell countingwas performed in at least six fields
per coverslip, with a total of 300 cells. Results are mean  SEM and
statistical significance ( p  0.05) was evaluated by one-way ANOVA
followed by Newman–Keuls multiple-comparison test.
Immunocytochemical evaluation of synaptotoxicity. After fixation with
4% paraformaldehyde, cells were permeabilized with PBS with 0.2%Tri-
ton X-100 for 2min and incubated with 3% of BSA in PBS for 30min for
the simultaneous immunocytochemical analysis of a presynaptic marker
[synaptophysin or 25 kDa synaptosomal-associated protein (SNAP-25)]
and a dendritic marker [microtubule-associated protein-2 (MAP-2)]
(Silva et al., 2007). Cells were incubated with rabbit anti-MAP-2 (1:400;
Santa Cruz Biotechnology) and mouse anti-synaptophysin (1:200;
Sigma-Aldrich) or mouse anti-SNAP-25 (1:200; Sigma-Aldrich) for 1 h.
After three washes with PBS, cells were incubated with anti-mouse or
anti-rabbit secondary antibody conjugated with a fluorophore (Alexa Fluor
488 and Alexa Fluor 594, respectively; 1:200; Invitrogen). The cells were
visualized by confocal microscopy (MRC 600).
Western blot analysis. Cultured hippocampal neurons were washed
twice with PBS and gently scraped with ice-cold lysis buffer composed of
25 mM HEPES-Na, 2 mM MgCl2, 1 mM EDTA, 1 mM EGTA, and supple-
mented with 2 mM DTT, 100 M phenylmethanesulfonyl fluoride
(PMSF), 2 mM orthovanadate, 50 mM sodium fluoride, and a protease
inhibitor mixture containing leupeptin, pepstatin A, chymostatin, and
aprotinin (1 mg/ml; all from Sigma-Aldrich). The synaptosomal extract
from rat or mice was solubilized in 5% SDS supplemented with 2 mM
DTT and 100 M PMSF and rapidly sonicated. After determining the
amount of protein using the BCA method, a 1/6 vol of 6 SDS-PAGE
sample buffer was added before storage at 20°C. Electrophoresis was
performed using a 10 or 7.5% SDS-PAGE gel after loading of different
amounts of each sample. Proteins were then transferred to PVDF
(polyvinylidene difluoride) membranes (GE Healthcare). Mem-
branes were blocked for 1 h at room temperature with 5% low-fat
milk in Tris-buffered saline or 3% bovine serum albumin (depending
on the antibodies used), pH 7.6, and containing 0.1% Tween 20 (TBS-
T). Membranes were then incubated overnight at 4°C with primary
antibodies, namely mouse anti-synaptophysin (1:5000–20,000),
mouse anti-SNAP-25 (1:5000–20,000), mouse anti-phospho-c-Jun
N-terminal kinase (JNK) (1:1000; Cell Signaling), or mouse anti-
phospho-p38 MAPK (1:1000; Cell Signaling). After washing with
TBS-T, membranes were incubated either with anti-mouse or anti-
rabbit IgG secondary antibodies (1:10,000–20,000 in TBS-T; Invitro-
gen). After washing, membranes were revealed using an ECF kit (GE
Healthcare) and visualized in a VersaDoc 3000 (Bio-Rad). The mem-
braneswere then reprobedand tested for-tubulin immunoreactivityusing
a mouse anti--tubulin antibody (1:10,000–20,000; Zymed), as previ-
ously described (Rebola et al., 2005). To determine phosphorylation ra-
tio of p38 and JNK, the membranes were reprobed with rabbit anti-total
JNK/SAPK (stress-activated protein kinase) or rabbit anti-p38 MAPK
total (both 1:1000; Cell Signaling).
HPLCquantification of adenosine levels in the incubationmedium.After
addition at time 0 of A1-42 (500 nM), cultured neurons were main-
tained at 37°C in a 5% CO2 humidified atmosphere with 1.2 ml of
medium, and samples (125 l) were collected from the incubation
medium after 0, 3, 12, 24, and 48 h. Each sample was filtered through
0.22 m filters (Millex-GV from Millipore; Interface) and stored at
20°C until analysis by reverse-phase HPLC, as previously described
(Cunha and Sebastia˜o, 1993). The quantification of adenosine was
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achieved by calculating the peak area and
then converting to concentration values
(correcting the change of incubation volume
over time) by calibration with known stan-
dards (0.03–3 M).
Statistical analysis. Results are presented as
mean  SEM. Data were analyzed with one-
way ANOVA and Newman–Keuls multiple-
comparison test (unless otherwise stated),





Western blot analysis of the A1-42 solu-
tions used in this study showed that they
were mainly constituted by monomers (4
kDa) and oligomers constituted by up to
four monomers (Fig. 1A). The intracere-
broventricular administration of A1-42
(2 nmol) led to an accumulation of A1-42
in the hippocampus (91.1  25.1 pg/mg
of protein; n  4; p  0.05), indicating
that 11.3  2.9% of the total amount of
administered A1-42 accumulated in hip-
pocampal tissue after 2 d. The hippocam-
pal A1-42 levels decreased over time (Fig.
1B), since only 26.6  8.9 pg/mg of pro-
tein (n 4) was detected after 15 d ( p
0.05; F  12.39 compared with A1-42
levels at 2 d).
The intracerebroventricular adminis-
tration ofA1-42 (2 nmol) caused a time-delayed (within 2weeks)
memory impairment, in agreement with previous reports
(Dall’Igna et al., 2007; Cunha et al., 2008), whereas it failed to
affect memory performance within 2 d, as evaluated both in the
Y-maze (Fig. 1D) or the object recognition test (Fig. 1E), without
changes in locomotor activity 2 or 15 d after A1-42 administra-
tion (data not shown). The control peptide (A42-1; 2 nmol)
changed neither Y-maze behavior nor locomotor activity (n 4)
(data not shown). This indicates that A1-42 might trigger a cas-
cade of events leading to a delayed rather than acute perturbation of
memoryperformance,which likely results fromtheactionof soluble
forms of A1-42 since we only found soluble A1-42 and no evidence
of the presence of A aggregates 15 d after the intracerebroventric-
ular administration of A1-42 (Fig. 1C).
Histological analysis of hippocampal sections, 2 weeks after
the injection of A1-42, revealed a preservation of cresyl violet
staining of Nissl bodies (Fig. 2A, showing CA3, which is identical
with CA1) and absence of neuronal loss evaluated by Fluoro-Jade
C, which is indistinguishable from control rats (Fig. 2B). Fur-
thermore, there was no evidence of microgliosis (evaluated by
CD11b immunoreactivity) or astrogliosis (evaluated by GFAP
immunoreactivity), neither after 15 d (data not shown) nor after
2 d (supplemental Fig. 1, available at www.jneurosci.org as sup-
plemental material) of A1-42 administration. Further excluding
acute toxic effects of A1-42 administration, there was no differ-
ence of cresyl violet or Fluoro-Jade C staining 2 d after the injec-
tion of A1-42 or vehicle (supplemental Fig. 1, available at www.
jneurosci.org as supplemental material). However, immunohisto-
chemical analysis revealed a decrease in the synaptic marker synap-
tophysin in hippocampal sections obtained from rats 15 d after
A1-42 injection (Fig. 2C), which was confirmed by quantitative
Western blot analysis. As illustrated in Figure 2D, synaptophysin
immunoreactivity was lower (25.7 4.3%; n 7; p 0.001) in
hippocampal membranes collected from rats 15 d after A1-42 ad-
ministration when compared with controls. In contrast, the
nonamyloidogenic A42-1 peptide failed to modify synaptophysin
immunoreactivity (data not shown).
Pharmacological blockade of adenosine A2A receptor
protects from A1-42-induced synaptotoxicity and
memory impairment
We then tested whether the blockade of A2ARs prevented the loss
of synaptic markers and memory impairment observed 2 weeks
after the intracerebroventricular administration of A1-42. For
that purpose, we used a selective A2AR antagonist (SCH58261) in
a dose (0.05 mg/kg, i.p.) that has previously been shown to pre-
serve memory performance without peripheral or locomotor ef-
fects (Dall’Igna et al., 2007; Cunha et al., 2008). As illustrated in
Figure 2C, SCH58261 (0.05 mg/kg) completely prevented the
decrease of synaptophysin immunoreactivity caused by A1-42.
In fact, synaptophysin immunoreactivity in hippocampal sec-
tions was indistinguishable in control conditions and in A1-42-
injected rats that were treated daily with SCH58261 (Fig. 2C).
Accordingly,Western blot analysis confirmed that the decrease in
synaptophysin density on A1-42 injection was prevented by
SCH58261 ( p 0.001) (Fig. 2D). In parallel, SCH58261was also
able to significantly ( p  0.001) prevent the decreased Y-maze
spontaneous alternation on A1-42 injection. In contrast,
SCH58261 did not modify synaptophysin immunoreactivity
(Fig. 2D) or spontaneous alternation in control rats (Fig. 2E) nor
did it affect locomotion in control orA1-42-treated rats (data not
shown).
Figure 1. Intracerebroventricular administration of soluble-amyloid peptides leads to an accumulation of soluble but
not aggregated forms of A in the hippocampus, causing delayed memory impairment without evident acute effects. The
Coomassie R-250 staining and 6E10 antibody-based Western blot analysis of the two different batches of A1-42 used
showed that they were mainly constituted by monomers and oligomer containing up to four monomers (A). Rats were
treated with A1-42 (2 nmol, i.c.v.) or water (control), which accumulated in the hippocampus after 2 and 15 d (B), as
measured by ELISA (n 4 rats treated with water and n 6 treated with A1-42). Congo Red and Thioflavin S staining (C)
failed to reveal the presence of A aggregates in hippocampal sections collected 15 d after A1-42 administration (images
representative of 3 animals). D, Spontaneous alternation in the Y-maze test of control and A1-42-treated rats after 2 or
15 d (n  6 animals treated with water and n  9 treated with A1-42). E, Object recognition index in the object
recognition test of control and A1-42-treated rats after 2 or 15 d (n 4 animals treated with water and n 6 –7 animals
treated with A1-42). Data in bar graphs are mean SEM; *p 0.05.
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Genetic inactivation of A2A receptor abolishes
A1-42-induced synaptotoxicity andmemory deficits
The memory impairment and loss of synaptic markers ob-
served in rats could also be reproduced on A1-42 administra-
tion in wild-type (C57BL/6) mice. In fact, 2 weeks after the
intracerebroventricular administration of A1-42 (2 nmol),WT
mice displayed a decreased memory performance, measured as a
decreased (23.0 1.7%; n 7; p 0.001) spontaneous alter-
nation in the Y-maze (Fig. 3A), without modification of locomo-
tor activity (Fig. 3B), and a decreased density of two synaptic
markers, synaptophysin (26.7  3.7%; n  4; p  0.001) and
SNAP-25 (25.8  2.3%; n  4; p  0.001) (Fig. 3C), when
comparedwith vehicle-injected (i.e., control)mice. Furthermore,
the histological analysis of hippocampal sections of A1-42-treated
WT mice showed the absence of the following: neuronal loss
evaluated by Fluoro-Jade C, microgliosis evaluated by CD11b
immunoreactivity, and astrogliosis evaluated by GFAP immuno-
reactivity (Fig. 3D, showing CA1 area, with similar results ob-
tained for CA3 area) (data not shown).
To confirm the key role of A2ARs in controlling A1-42-
induced loss of synaptic markers and memory impairment, we
tested the effects of A1-42 in A2AR KO mice. The A2AR genetic
inactivation in KOmice led to a decrease in the number of cross-
ings (30 7; n 14; p 0.05) and rearings (7 2; n 14; p
0.05) when compared with WT mice; however, this does not
affect the Y-maze alternation, on comparison of saline-injected
WT and KOmice (Fig. 3B). As shown in Figure 3, A1-42 admin-
istration induced neither loss of synaptic
markers nor memory impairment in
A2AR KO mice. Indeed, A1-42-injected
A2AR KO mice did not display a decrease
of spontaneous alteration in the Y-maze
(Fig. 3A) or a decrease in the density of
the synaptic markers, synaptophysin or
SNAP-25 (Fig. 3C). Furthermore, vehicle-
or A1-42-injected A2AR KO mice did not
display cell death, microgliosis, or astro-
gliosis (Fig. 3D).
Blockade of A2A receptors prevents
A1-42-induced dysfunction of
purified nerve terminals
The observations that A1-42 triggered an
A2AR-sensitive selective loss of synaptic
markers prompted the hypothesis that
this A2AR-sensitive A1-42-induced toxic-
ity could be replicated in enriched nerve
terminals (synaptosomes). Previous stud-
ies have already reported that exposure of
synaptosomes to -amyloid peptides trig-
gers mitochondrial dysfunction (Mattson
et al., 1998), which has been argued to
be a key feature of Alzheimer’s disease
(Moreira et al., 2006). Accordingly, syn-
aptosomes exposed for 2 h to 500 nM
A1-42 display a decrease (8.3  3.6%
compared with control; n 4; p 0.001)
in MTT reduction (Fig. 4A), which mea-
sures the redox status of synaptosomes,
indicative of synaptosomal viability
(Mattson et al., 1998; Silva et al., 2007).
Furthermore, a decrease in TMRM ac-
cumulation, indicative of decreasedmito-
chondrial membrane potential (11.5 2.5%; n 8; p 0.05)
in A1-42-treated synaptosomes was also observed (Fig. 4B).
On blockade of A2ARs with SCH58261 (50 nM), there was a
prevention of the A1-42-induced disruption of the functionality
(Fig. 4A) and mitochondrial membrane potential of synapto-
somes (Fig. 4B), whereas SCH58261 was devoid of effects in con-
trol synaptosomes (i.e., not treated with A1-42) or treated with
the nonamyloidogenic A42-1 peptide (data not shown).
Blockade of A2A receptor protects hippocampal neurons from
A1-42-induced toxicity
To investigate the mechanism involved in the A2AR-mediated
control of A1-42-induced neurotoxicity, we used a cell culture
model, namely, primary cultures of hippocampal neurons. Cul-
tured hippocampal neurons were exposed for 12, 24, and 48 h to
500 nMA1-42, and neuronal death was analyzed by double label-
ing with Syto-13 and PI (Fig. 5A,B). After 12 h of exposure to
A1-42, hippocampal neurons did not present any significant de-
crease (1.0 1.0%; n 5; p 0.05) of either cell viability (Fig.
5A) or number of apoptotic-like neurons (Fig. 5B) when com-
pared with control neurons (either not exposed to A1-42 or ex-
posed to the nonamyloidogenic A42-1 peptide). In fact, a
decrease of cell viability (9.0 2.0%;n 5; p 0.001)was only
observed 24 h after A1-42 exposure (Fig. 5A), which was accom-
panied by an increased number of apoptotic-like neurons (5 
1%; n  5; p  0.001) (Fig. 5B). This A1-42-induced neuronal
death was larger after 48 h of exposure to A1-42, as evaluated by
Figure 2. -Amyloid administration causes a selective synaptotoxicity andmemory dysfunction, which is prevented by block-
ade of adenosine A2A receptors. Rats were treated with A1-42 (2 nmol, i.c.v.) or water (control). The A2AR antagonist SCH58261
(0.05 mg/kg, i.p.) was administered daily starting 30 min before A, and rats were behaviorally analyzed after 15 d. A, B, Cresyl
violet staining of Nissl bodies (A) and Fluoro-Jade C staining of neuronal death (B) in hippocampal sections from control and
A1-42-injected rats. C, D, Immunohistochemical labeling with anti-synaptophysin in hippocampal sections from rats injected
with water (control), A1-42 (A), SCH58261 (SCH), and A plus SCH (images representative of 5 experiments) (C) and quantifi-
cation by Western blot analysis (D) of synaptophysin immunoreactivity in hippocampal membranes from these different experi-
mental groups (data aremean SEM from7 experiments; *p 0.05). E, Spontaneous alternation in the Y-maze test of the same
groups of rats, as well as rats injected with the nonamyloidogenic scrambled A1-42 peptide (scA) (data are mean SEM from
9 rats; *p 0.001).
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the decreased number of viable neurons
(12.3  3.7%; n  5; p  0.001)
(Fig. 5A) and the increased number of
apoptotic-like neurons (9  2%; n  5;
p  0.001) (Fig. 5B), indicating a time-
dependent evolving profile of A1-42-
induced neurodegeneration. As occurred
in vivo and in native brain preparations,
this A1-42-induced neurotoxicity was pre-
vented by the A2AR antagonist, SCH58261
(50 nM), which did not affect neuronal via-
bility in control neurons (Fig. 5C,D).
We next investigated whether the ex-
posure of cultured neurons to A1-42
caused an initial synaptotoxicity preced-
ing neuronal death. Since we observed
that neurons incubated for 12 h with
A1-42 did not display loss of viability or
damage, we evaluated whether A1-42-
induced synaptotoxicity would be present
after 12 h of exposure to A1-42, by evalu-
ating the double staining of MAP-2 and
synaptophysin or SNAP-25. As shown in
Figure 6 (and in supplemental Fig. 2,
available at www.jneurosci.org as supple-
mental material), there was a retraction of
MAP-2-labeled segments and a decrease
in the number of synaptophysin-imm-
unoreactive spots after 12 h of exposure to
A1-42 (i.e., at the time when neuronal
damage is not yet present) (Fig. 5). To
quantify this A1-42-induced synaptotox-
icity, we used Western blotting analysis,
which showed a decrease in the density of
synaptophysin (30.3 7.5%; n 6; p
0.05) and SNAP-25 (37.0  6.6%; n 
6; p  0.05) on exposure to A1-42. As
occurred in vivo, this initial and evolving
A1-42-induced synaptotoxicity in neuro-
nal cultures was also prevented by A2AR
blockade with the selective A2AR antago-
nist, SCH58261 (50 nM) (Fig. 6A; supple-
mental Fig. 2, available at www.jneurosci.
org as supplemental material).
This observation that SCH58261 pre-
vents A1-42-induced neurotoxicity but is
devoid of effects in controls suggests that
the levels of extracellular adenosinemight
be increased on exposure to A1-42, which
is in accordance with the general concept that noxious stimuli are
expected to increase the extracellular levels of adenosine (Fred-
holm et al., 2005). As predicted, incubation of hippocampal
neurons with A1-42 (500 nM) caused a100% increase of the
extracellular concentration of adenosine (104.7  38.8 nM;
n  5; p  0.05) after 3 h that is persistent until 48 h of
incubation (Fig. 6C).
Signaling pathways involved in the neuroprotection
afforded by A2A receptor blockade against
A1-42-induced neurotoxicity
Since one of main transducing systems operated by A2ARs in-
volves cAMP/protein kinase A (PKA) pathway (Fredholm et al.,
2005), we investigated whether the neuroprotective effects af-
forded by SCH58261 involved this pathway. As observed in the
Figure 7A, the manipulation of the cAMP/PKA pathway influ-
ences A1-42-induced neurotoxicity, as described by others
(Parvathenani et al., 2000;Gong et al., 2004; Shrestha et al., 2006).
In fact, the activation of PKA with the cell-permeable cAMP an-
alog 8-Br-cAMP (200 M) attenuated A1-42-induced neurotox-
icity, an effect prevented by the PKA inhibitor H-89 (1 M) (Fig.
7A). However, the neuroprotection by SCH58261 persisted even
in the presence of H-89, ruling out the participation of cAMP/
PKApathway in the neuroprotection resulting from the blockade
of A2ARs (Fig. 7A).
It is also suggested that deregulation of the MAPK pathways,
namely of JNK and p38 MAPK family of proteins, might play a
role in the intracellular mechanisms of neurodegeneration, in
Figure 3. Genetic inactivation of adenosine A2A receptors prevents -amyloid-induced synaptotoxicity and memory impairment.
Wild-type C57BL/6 or A2AR KO mice were treated with A1-42 (2 nmol, i.c.v.) or water [control (CTR)] and analyzed after 15 d.
A,B, Spontaneousalternation in theY-maze test (A) andspontaneous locomotionevaluated inanopen-fieldarena (B) (dataaremean
SEM of n 7mice per experimental group; *p 0.001). C, Western blot comparing synaptophysin and SNAP-25 immunoreactivity in
hippocampalmembranes obtained fromwild-type or A2ARKOmice injectedwithwater (CTR) or A1-42 (data aremean SEMofn4
mice per experimental group; *p 0.001). D, Fluoro-Jade C staining of neuronal death, CD11-b immunohistochemistry evaluating
microgliosis, and GFAP immunohistochemistry evaluating astrogliosis in hippocampal sections fromwild-type or A2AR KOmice injected
withwater (CTR) or A1-42 (images representative ofn 4mice per experimental group).
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particular in A1-42-induced neurotoxicity (Troy et al., 2001;
Minogue et al., 2003;Wang et al., 2004b; Zhu et al., 2005; Mun˜oz
et al., 2007), and A2ARs can also signal through the MAPK path-
way (for review, see Fredholm et al., 2005). To test the involve-
ment of JNK and p38 MAPK in the A2AR-mediated protection
against A1-42-induced neurotoxicity, we first investigated the
time course of A1-42-induced activation of p38 MAPK and JNK
(evaluated as their degree of phosphorylation) to determine the
time points at which this process occurs (data not shown). It was
found that, after 2 h of incubation with A1-42 (500 nM), there
was an increase of JNK (69 21%; n 6; p 0.01) (Fig. 7B) and
p38 MAPK (41  15%; n  7; p  0.05) phosphorylation (Fig.
7C). At this time point, A2AR blockade with SCH58261 (50 nM)
increased the A1-42-induced JNK phosphorylation (210 74%;
n  6; p  0.01), whereas it abolished the A1-42-induced p38
MAPK phosphorylation (Fig. 7B,C). Confirming the key role of
p38MAPK in the A1-42-induced neurotoxicity (Zhu et al., 2005;
Mun˜oz et al., 2007; Origlia et al., 2008), we found that the p38
MAPK inhibitor SB202190 (200 nM) pre-
vented the A1-42-induced loss of neuro-
nal viability and increased number of
apoptotic-like neurons (Fig. 7D).
Discussion
The present results provide the first
demonstration that blockade of a mem-
brane receptor enriched in hippocampal
synapses, namely, A2ARs, abolishes the
loss of nerve terminal markers (i.e., syn-
aptotoxicity) triggered by A to culmi-
nate in memory dysfunction, the two
cardinal features of early phases of AD.
These results are relevant for the following
three different reasons: (1) they provide
evidence that control of a presynaptic
modulation system that prevents synap-
totoxicity also prevents memory dysfunc-
tion, strengthening the hypothesis that
synaptic dysfunction is a precocious core
modification of AD; (2) they provide ad-
ditional evidence that A2ARs, the density
of which is increased in AD (Albasanz et
al., 2008), are a novel promising target to
control AD; (3) they provide a clear dem-
onstration that neuroprotection afforded
by A2AR blockade is independent of
cAMP/PKA transducing system and re-
sults suggest that it is instead mediated by
p38 MAPK.
We now observed that intracerebro-
ventricular administration of soluble
forms of A1-42 (Resende et al., 2008)
caused a delayed loss of memory perfor-
mance only after 15 d that was selectively
associated with loss of synaptic markers.
In fact, the only morphological change
found in the hippocampus of A-injected
rodents displaying memory deficits was
the lossof synapticmarkers,whereasneither
overt neuronal damage nor astrogliosis nor
microgliosis were observed, neither 15
nor 2 d after A1-42 administration. Ac-
cordingly, in cultured neurons (in
which peripheral, vascular, glial, or im-
mune influences are absent), we also found that exposure to
A caused first a synaptotoxicity (Roselli et al., 2005; Calabr-
ese et al., 2007; Shankar et al., 2007; Evans et al., 2008), which
is only later followed by overt neuronal damage. Further
strengthening that A causes direct effects on nerve terminals,
we showed that A indeed directly impairs synaptosomal
function, as observed by others (Mattson et al., 1998; Arias et
al., 2002). Together, these observations indicate that A,
which can bind to synaptic proteins (Lacor et al., 2007) and
accumulates synaptically in AD patients (Takahashi et al.,
2002; Gylys et al., 2004; Fein et al., 2008), causes a primordial
synaptotoxicity that precedes overt neuronal damage, as oc-
curs in different transgenic animal models of AD (Hsia et al.,
1999; Mucke et al., 2000; Oddo et al., 2003; Wu et al., 2004;
Jacobsen et al., 2006) and in frontal cortical and hippocampal
regions early in AD (Scheff et al., 2006, 2007). It should be
stressed that we only obtained evidence that A1-42 caused loss
Figure4. Exposure toA1-42 directly decreases the function of rat hippocampal synaptosomes,which is preventedbyblockade
of adenosine A2A receptors. Synaptosomes were incubated for 2 h with 500 nM A1-42 or Krebs’ buffer, in the absence or presence
of the A2AR antagonist, SCH58261 (50 nM), added 15min before. A, Synaptosomal viability was measured using the MTT assay
(data are mean  SEM of n  4; *p  0.05). B, Measurement of mitochondrial membrane potential 	 (difference
between the final and initial baseline) using the TMRM indicator after adding FCCP and oligomycin (data are mean
SEM of n 8; *p 0.05).
Figure 5. Temporal analysis of neuronal death caused by A1-42 and neuroprotection by blockade of adenosine A2A
receptors. Hippocampal neurons were preincubated with the A2AR antagonist SCH58261 (50 nM) 15 min before addition of
500 nM A1-42. Neurons were double labeled with Syto-13 and PI probes. Viable neurons presented green nuclei stained
with Syto-13, whereas apoptotic neurons presented shrinkage nuclei stained with PI and Syto-13. A, B, A-induced
neuronal death is time dependent. C, D, Blockade of A2AR with SCH58261 prevents neuronal death on 48 h of incubation
with A. A total of 300 cells per coverslip was counted. Results are means  SEM of duplicate coverslips from five
independent hippocampal cultures; *p 0.05.
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of synaptic markers, modification of the
viability of nerve terminals (synapto-
somes), and degeneration of synapses,
which we collectively called synaptotox-
icity; however, it remains to be deter-
mined to what extent this synaptotoxicity
relates to the known A-induced func-
tional impairment of hippocampal syn-
apses (Venkitaramani et al., 2007).
This tight relationship between synap-
totoxicity andmemory dysfunction is fur-
ther strengthened by the key observation
of the present study [i.e., that blockade of
A2ARs (pharmacological or genetic inacti-
vation) simultaneously prevents synapto-
toxicity and memory impairment caused
by A administration]. Furthermore,
the initial synaptotoxicity that precedes
overt neuronal damage on exposure of
cultured neurons to A was also pre-
vented by A2AR blockade. Finally, the
direct A-induced impairment of nerve
terminal function was also prevented by
A2AR blockade. All these observations
are in agreement with the predominant
synaptic localization of A2ARs in cortical
regions (Rebola et al., 2005). These synap-
tic A2ARs play a key role controlling
NMDA-dependent synaptic plasticity
(Rebola et al., 2008), which is severely
hampered early in AD (Roselli et al., 2005;
Shankar et al., 2007; Venkitaramani et al.,
2007). Thus, synaptic A2ARs normalize
the function of these glutamatergic syn-
apses (for review, see Cunha, 2008a),
which are dysfunctional in AD (Bell et al.,
2007), and their blockade prevents synap-
totoxicity caused by different stimuli
(Cunha et al., 2006; Silva et al., 2007) that
leads to subsequent overt neurodegenera-
tion on stressful conditions (Silva et al.,
2007). This implies that the ability of
A2ARs to control memory impairment
should be particularly evident when syn-
aptotoxicity is involved. Accordingly, we
have previously shown that A2AR block-
ade can prevent memory impairment caused by A, which we
now show to involve synaptotoxicity, but are ineffective in con-
trolling acute memory dysfunction caused by pharmacological
manipulation of the cholinergic or glutamatergic systems (Cunha
et al., 2008), which is reversible and does not involve synaptotox-
icity. Overall, this supports the notion that prevention of syn-
aptic impairment on A2AR blockademay underlie the ability of
A2AR antagonists to prevent A-induced memory impair-
ment, which illustrates that control of synaptic dysfunction
may be a relevant strategy to alleviate memory dysfunction
associatedwithneurodegenerative conditions (Colemanet al., 2004;
Wishart et al., 2006).
This putative relevance of targeting A2ARs to control memory
impairment associated with neurodegenerative conditions is
strongly supported by the ability of caffeine to counteract the
development of neurodegenerative conditions and, in partic-
ular, the development of cognitive deficits (for review, see
Cunha, 2008b; Takahashi et al., 2008). In fact, although it is
doubtful that caffeine is a cognitive enhancer, its long-term
consumption is clearly associated with decreased memory im-
pairment caused by different perturbing conditions (Cunha,
2008b; Takahashi et al., 2008) such as on aging (Ritchie et al.,
2007; Costa et al., 2008a) or Alzheimer’s disease (Maia and de
Mendonc¸a, 2002; Eskelinen et al., 2009). The only known
mechanisms of action of nontoxic doses of caffeine are the
antagonism of adenosine receptors (Fredholm et al., 1999).
Animal studies indicate that the ability of chronic caffeine
consumption to prevent memory deterioration caused by dif-
ferent insults is mimicked by antagonists of A2ARs rather than
A1Rs (for review, see Cunha, 2008b; Takahashi et al., 2008).
Accordingly, we have previously shown that the beneficial ef-
fects of caffeine on A-induced neurotoxicity and memory
impairment are mimicked by antagonists of A2ARs but not of
A1Rs (Dall’Igna et al., 2003, 2007). Thus, it is tempting to
Figure 6. Temporal analysis of synaptotoxicity caused by A1-42 and neuroprotection by blockade of adenosine A2A
receptors. Hippocampal neurons were preincubated with the A2AR antagonist SCH58261 (50 nM) 15 min before addition of
500 nM A1-42. Hippocampal neurons were double-labeled for MAP-2 (red) and synaptophysin (green) after 12 h (A), 24 h
(B), and 48 h (C) of incubation and analyzed by confocal microscopy. Magnification, 400. A1-42 causes a decrease of
MAP-2 and synaptophysin immunoreactivities at all type points, which is prevented by SCH58261 and is not mimicked by
the nonamyloidogenic scrambled peptide A42-1. D, Western blot analysis (15 g of protein loaded in each lane) quan-
tifying the loss of synaptophysin and SNAP-25 immunoreactivities in cultures treated with A, which is prevented by
SCH58261 (data are mean SEM of 6 independent cultures; *p 0.05). E, Time course analysis of the extracellular levels
of adenosine (quantified by HPLC) in hippocampal neurons incubated with A (data are mean SEM of 5 independent
cultures; *p 0.05).
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propose that the promising beneficial effects of caffeine con-
sumption as a strategy to prevent the burden of AD might be
related to the synaptoprotective effect afforded by A2AR block-
ade. This proposal does not exclude other possible concurring
mechanisms by which caffeine may afford protection in AD,
such as control of A production (Arendash et al., 2006),
control of the disruption of the blood–brain barrier (Chen et
al., 2008), or control of neuroinflammation (Angulo et al.,
2003). Thus, although the present data combining the use of
fractionated nerve terminals, cultured neurons, and in vivo
models strongly argue for the predominant importance of
synaptic A2ARs in controlling A-induced neurotoxicity, it
does not exclude the possibility that other mechanisms may
also contribute for neuroprotection against A-induced neu-
rotoxicity and memory impairment.
Finally, this study demonstrates that neuroprotection result-
ing from A2AR blockade does not involve the cAMP/protein ki-
nase A transducing system but instead
depends on control of p38MAPK. In fact,
the mechanisms by which A2ARs impact
on neurodegeneration are still unresolved
(for discussion, see Cunha, 2005; Chen et
al., 2007). For historical reasons, there is a
general consensus that A2ARs signal
through activation of the adenylate cy-
clase/cAMP/PKA pathway (Fredholm et
al., 2005). However, this is unlikely to be
the relevant transducing system related to
A2AR control of neurodegeneration since
enhanced cAMP levels afford neuropro-
tection against A-induced neurotoxicity
(Parvathenani et al., 2000; Gong et al.,
2004; Shrestha et al., 2006), whereas it is
A2AR blockade (expected to decrease
cAMP levels) that affords neuroprotec-
tion. Accordingly, neuroprotection af-
forded by A2AR blockade against A-
induced neurotoxicity was insensitive to
the PKA inhibitor H-89, which prevented
neuroprotection afforded by enhanced
cAMP levels. Other transducing pathways
have been documented to control degen-
eration in ADmodels, namely, theMAPK
pathways (Zhu et al., 2005; Mun˜oz et al.,
2007; Origlia et al., 2008), and, accord-
ingly, we confirmed that A triggered ac-
tivation of both JNK and p38 MAPKs.
Interestingly, we observed that A2AR
blockade prevented the A-induced acti-
vation of p38, whereas it enhanced JNK
phosphorylation, an aspect that needs at-
tention in view of the association between
JNK activation and neurodegeneration
(Wang et al., 2004a). Given that inhibi-
tion of p38 activation is sufficient to pre-
vent A-induced neurotoxicity, as also
observed by others (Zhu et al., 2005;
Mun˜oz et al., 2007; Origlia et al., 2008),
this indicates that A2ARs signal through
p38MAPK to control neurodegeneration.
Indeed, previous studies have docu-
mented the ability of A2ARs to control
MAPK pathways in a cAMP-independent
manner (Schulte and Fredholm, 2003; Fredholm et al., 2005;
Gsandtner et al., 2005), and it has previously been suggested
that the control by A2ARs of the ischemia-induced brain dam-
age was related to the ability of A2AR antagonists to blunt the
ischemia-induced accumulation of phosphorylated forms of
p38 (Melani et al., 2006). Thus, the present results indicate
that A2ARs control A-induced neurotoxicity through control
of p38 MAPK phosphorylation. However, this conclusion de-
rives solely from in vitro studies and remains to be confirmed
in vivo.
In summary, the present observations that blockade of
A2ARs prevents the early synaptotoxicity in both in vitro and
in vivo models pertinent to AD, strengthen the interest of
exploring the prophylactic and therapeutic potential of A2AR
antagonists, which are about to be introduced into clinical
practice as novel antiparkinsonian drugs (Schwarzschild et al.,
2006).
Figure 7. The neuroprotection afforded by blockade of adenosine A2A receptors against A1-42-induced neurotoxicity involves
the p38MAPK rather than the cAMP/protein kinase A signaling pathway. Hippocampal neurons were preincubatedwith the A2AR
antagonist SCH58261 (50nM) orwith the cAMPanalog 8-Br-cAMP (200M) 15minbefore addition of 500nMA1-42. All inhibitors
tested were added 30 min A1-42. A, Neuroprotection by SCH58261 does not involve the cAMP/PKA signaling pathway since the
PKA inhibitor H-89 (1M) prevents the neuroprotection afforded by 8-Br-cAMP, but fails to modify the neuroprotection afforded
by SCH58261, as evaluated after 24 h of exposure to A1-42 (*p 0.05 vs control
#p 0.05 vs A1-42;
&p 0.05 vs A1-42
8-Br-cAMP).B, C, A1-42 triggered the activation of JNK (B) and p38MAPK (C), evaluated by their degree of phosphorylation after
2 h, and SCH58261 enhanced JNK phosphorylation, whereas it blocked p38MAPK phosphorylation (data aremean SEM from 6
independent cultures; *p 0.05 vs control; **p 0.05 vs effect of A).D, The p38MAPK inhibitor SB202190 prevents neuronal
death induced by A1-42 (data are mean SEM from 5 independent cultures; *p 0.05 vs control).
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